Product Pathways
BCP0026 Belinostat
Belinostat (PXD101) is a novel hydroxamate-type inhibitor of histone deacetylase (HDAC) activity.
BCP0126 Trichostatin A
Trichostatin A /TSA is a potent, reversible inhibitor of histone deacetylase (HDAC).
BCP0062 JNJ-26481585
An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.
BCP0067 LAQ824 (NVP-LAQ824)
LAQ824,a histone deacetylase inhibitor.
BCP0068 LBH-589(Panobinostat)
LBH589 is a hydroxamic acid and acts as a non-selective HDAC inhibitor with IC5o of HDAC1 to be 0.23 nM.
BCP0074 MGCD0103(Mocetinostat)
MGCD0103,an orally available small molecule,binds to and inhibits Class 1 isoforms of HDAC.
BCP0078 MS-275(Entinostat)
MS-275(Entinostat) is an HDAC inhibitor of HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively.
BCP0090 PCI-24781
PCI-24781 (CRA-024781) is a novel broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials for cancer.
BCP0134 Vorinostat (SAHA)
HDAC inhibitor and shows IC 50 of 10 nM (HDAC-1) and 300 nM.
BCP0155 Resveratrol
Resveratrol is a phytoalexin produced naturally by several plants with anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects .
第一页 1 2 3 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.